When IL-17 inhibitors fail

real-life evidence to switch from secukinumab to adalimumab or ustekinumab

Giovanni Damiani, Rosalynn Rz Conic, Valerio de Vita, Antonio Costanzo, Roberto Regazzini, Paolo Dm Pigatto, Nicola L Bragazzi, Alessia Pacifico, Piergiorgio Malagoli

Research output: Contribution to journalArticle

Abstract

Psoriasis is a chronic, systemic inflammatory disease that in the moderate to severe forms may benefit of biologics, namely TNF and IL-12/23 and IL-17 inhibitors. Loss of response, lack of response or discontinuation due to adverse events represent a concrete therapeutic challenge for dermatologists that have to switch patients to other treatments. Although some evidences already exist toward the switch from IL-12/23 and TNF inhibitors to IL-17 inhibitors, conversely nothing is present toward the switch from IL-17 inhibitors to IL-12/23 and TNF inhibitors. We performed a real-life study enrolling 50 patients randomly switched to adalimuamb, a TNF inhibitor, or ustekinumab, an IL-12/23 inhibitor. Our observational study suggests that switching from IL-17i to TNFi and IL-12/23i is a safe and effective therapeutic strategy. This article is protected by copyright. All rights reserved.

Original languageEnglish
Pages (from-to)e12793
JournalDermatologic Therapy
DOIs
Publication statusE-pub ahead of print - Dec 5 2018

Fingerprint

Interleukin-17
Interleukin-23
Interleukin-12
Biological Products
Psoriasis
Observational Studies
Therapeutics
secukinumab
Adalimumab
Ustekinumab

Cite this

Damiani, G., Conic, R. R., de Vita, V., Costanzo, A., Regazzini, R., Pigatto, P. D., ... Malagoli, P. (2018). When IL-17 inhibitors fail: real-life evidence to switch from secukinumab to adalimumab or ustekinumab. Dermatologic Therapy, e12793. https://doi.org/10.1111/dth.12793

When IL-17 inhibitors fail : real-life evidence to switch from secukinumab to adalimumab or ustekinumab. / Damiani, Giovanni; Conic, Rosalynn Rz; de Vita, Valerio; Costanzo, Antonio; Regazzini, Roberto; Pigatto, Paolo Dm; Bragazzi, Nicola L; Pacifico, Alessia; Malagoli, Piergiorgio.

In: Dermatologic Therapy, 05.12.2018, p. e12793.

Research output: Contribution to journalArticle

Damiani, G, Conic, RR, de Vita, V, Costanzo, A, Regazzini, R, Pigatto, PD, Bragazzi, NL, Pacifico, A & Malagoli, P 2018, 'When IL-17 inhibitors fail: real-life evidence to switch from secukinumab to adalimumab or ustekinumab', Dermatologic Therapy, pp. e12793. https://doi.org/10.1111/dth.12793
Damiani, Giovanni ; Conic, Rosalynn Rz ; de Vita, Valerio ; Costanzo, Antonio ; Regazzini, Roberto ; Pigatto, Paolo Dm ; Bragazzi, Nicola L ; Pacifico, Alessia ; Malagoli, Piergiorgio. / When IL-17 inhibitors fail : real-life evidence to switch from secukinumab to adalimumab or ustekinumab. In: Dermatologic Therapy. 2018 ; pp. e12793.
@article{c92e7ee5b5904debbaca6764244e6100,
title = "When IL-17 inhibitors fail: real-life evidence to switch from secukinumab to adalimumab or ustekinumab",
abstract = "Psoriasis is a chronic, systemic inflammatory disease that in the moderate to severe forms may benefit of biologics, namely TNF and IL-12/23 and IL-17 inhibitors. Loss of response, lack of response or discontinuation due to adverse events represent a concrete therapeutic challenge for dermatologists that have to switch patients to other treatments. Although some evidences already exist toward the switch from IL-12/23 and TNF inhibitors to IL-17 inhibitors, conversely nothing is present toward the switch from IL-17 inhibitors to IL-12/23 and TNF inhibitors. We performed a real-life study enrolling 50 patients randomly switched to adalimuamb, a TNF inhibitor, or ustekinumab, an IL-12/23 inhibitor. Our observational study suggests that switching from IL-17i to TNFi and IL-12/23i is a safe and effective therapeutic strategy. This article is protected by copyright. All rights reserved.",
author = "Giovanni Damiani and Conic, {Rosalynn Rz} and {de Vita}, Valerio and Antonio Costanzo and Roberto Regazzini and Pigatto, {Paolo Dm} and Bragazzi, {Nicola L} and Alessia Pacifico and Piergiorgio Malagoli",
note = "This article is protected by copyright. All rights reserved.",
year = "2018",
month = "12",
day = "5",
doi = "10.1111/dth.12793",
language = "English",
pages = "e12793",
journal = "Dermatologic Therapy",
issn = "1396-0296",
publisher = "Blackwell Publishing Inc.",

}

TY - JOUR

T1 - When IL-17 inhibitors fail

T2 - real-life evidence to switch from secukinumab to adalimumab or ustekinumab

AU - Damiani, Giovanni

AU - Conic, Rosalynn Rz

AU - de Vita, Valerio

AU - Costanzo, Antonio

AU - Regazzini, Roberto

AU - Pigatto, Paolo Dm

AU - Bragazzi, Nicola L

AU - Pacifico, Alessia

AU - Malagoli, Piergiorgio

N1 - This article is protected by copyright. All rights reserved.

PY - 2018/12/5

Y1 - 2018/12/5

N2 - Psoriasis is a chronic, systemic inflammatory disease that in the moderate to severe forms may benefit of biologics, namely TNF and IL-12/23 and IL-17 inhibitors. Loss of response, lack of response or discontinuation due to adverse events represent a concrete therapeutic challenge for dermatologists that have to switch patients to other treatments. Although some evidences already exist toward the switch from IL-12/23 and TNF inhibitors to IL-17 inhibitors, conversely nothing is present toward the switch from IL-17 inhibitors to IL-12/23 and TNF inhibitors. We performed a real-life study enrolling 50 patients randomly switched to adalimuamb, a TNF inhibitor, or ustekinumab, an IL-12/23 inhibitor. Our observational study suggests that switching from IL-17i to TNFi and IL-12/23i is a safe and effective therapeutic strategy. This article is protected by copyright. All rights reserved.

AB - Psoriasis is a chronic, systemic inflammatory disease that in the moderate to severe forms may benefit of biologics, namely TNF and IL-12/23 and IL-17 inhibitors. Loss of response, lack of response or discontinuation due to adverse events represent a concrete therapeutic challenge for dermatologists that have to switch patients to other treatments. Although some evidences already exist toward the switch from IL-12/23 and TNF inhibitors to IL-17 inhibitors, conversely nothing is present toward the switch from IL-17 inhibitors to IL-12/23 and TNF inhibitors. We performed a real-life study enrolling 50 patients randomly switched to adalimuamb, a TNF inhibitor, or ustekinumab, an IL-12/23 inhibitor. Our observational study suggests that switching from IL-17i to TNFi and IL-12/23i is a safe and effective therapeutic strategy. This article is protected by copyright. All rights reserved.

U2 - 10.1111/dth.12793

DO - 10.1111/dth.12793

M3 - Article

SP - e12793

JO - Dermatologic Therapy

JF - Dermatologic Therapy

SN - 1396-0296

ER -